BRAND NAME / COMPANY / REIMBURSEMENT AND LOGISTICS PROGRAM (ORIGINAL MARKET DATE)

Velsipity®/Pfizer/PfizerFlex™ (2024)

APPROVED CLINICAL INDICATIONS

(may vary within provinces – refer to local patient support program)

Crohn’s disease
Ulcerative colitis

CLASS

Monoclonal antibody
Tumour necrosis factor (TNF) blocking agent

ACTION

IBD causes the immune system to produce an excess amount of TNFα, which causes inflammation. Anti-TNFα is a protein that works to bind TNFα and block inflammation.